|Table of Contents|

Drug characteristics and monitoring points of anlotinib in real world treatment of cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1663-1668
Research Field:
Publishing date:

Info

Title:
Drug characteristics and monitoring points of anlotinib in real world treatment of cancer patients
Author(s):
ZHANG Xialan; YUAN Jing; WU Bin
Department of Pharmacy,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangsu Suzhou 215009,China.
Keywords:
anlotinib; the real world; tumor patient; rational drug use; adverse reaction; pharmaceutical care
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.09.016
Abstract:
Objective:To analyze the characteristics and main points of monitoring of anlotinib therapy in the real world.Methods:A retrospective investigation was conducted to summarize the treatment information of patients who used anlotinib in our hospital from 1st January 2020 to 31st December 2022 through His system.We collected the basic information of patients,medication information,clinical efficacy and adverse reactions.Results:A total of 98 patients taking anlotinib were included.There were 60 males and 38 females with an average age of (63.08±9.22) years old.The anlotinib was mainly used for lung cancer,bile duct cancer,fallopian tube cancer of stage Ⅳ tumor patients.Most of the TCM syndrome types were Qi-yin deficiency or spleen deficiency dampness.The KPS scores of patients were mainly 80 and 70 points.Before medication,low white blood cells,high transaminase,low blood sodium and abnormal thyroid function were common.Most of the patients took 10mg qd of anlotinib.More patients took allotinib alone,combined with immune drugs or proprietary Chinese medicines.About 52.04% of the patients had partial response and stability,and 29.59% had progress.Common adverse reactions were fatigue,positive urinary protein,elevated blood pressure,and thrombocytopenia.Conclusion:Doctors should pay attention to the safety and rational use of anlotinib.Clinical pharmacists should do a good job of medication replacement and pay attention to the interaction between anrotinib and other drugs.Clinical pharmacists should strengthen monitoring of related adverse events,especially such as elevated blood pressure,bleeding,positive proteinuria,hypothyroidism and decreased platelet count.We aim to reduce the risk of medication.

References:

［1]LIN B,SONG X,YANG D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1［J］.Gene,2018,654:77-86.
［2]王睿晴，张艳华.抗肿瘤分子靶向药物安罗替尼的临床研究进展［J］.中国新药杂志,2018,27(23):2770-2774. WANG RQ,ZHANG YH.Advances in clinical research of antitumor targeting drug anlotinib［J］.China Journal of New Drugs,2018,27(23):2770-2774.
［3]田甜,何淼,吴飞,等.安罗替尼治疗非小细胞肺癌的近期疗效及对血清肿瘤标志物CTC VGEF水平和毒副作用的影响［J］.河北医学,2021,27(11):1908-1912. TIAN T,HE M,WU F,et al.Short-term efficacy of anlotinib in the treatment of non-small cell lung cancer and its influence on serum tumor markers CTC VGEF and side effects［J］.Hebei Medicine,2021,27(11):1908-1912.
［4]HAN B,KAI L,WANG Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,11(4):1569-1575.
［5]SHEN G,ZHENG F,REN D,et al.Anlotinib:a novel multi-targeting tyrosine kinase inhibitor in clinical development［J］.J Hematol Oncol,2018,11(1):120.
［6]宋晴.安罗替尼联合治疗在肿瘤治疗中的研究进展［J］.山东大学耳鼻喉眼学报,2022,36(5):106-112. SONG Q.Research progress of anlotinib combination therapy in cancer treatment［J］.Journal of Otolaryngology,Shandong University,2022,36(5):106-112.
［7]林洪生.恶性肿瘤中医诊疗指南［M］.北京：人民卫生出版社,2014:20-33. LIN HS.Guidelines of diagnosis and therapy in oncology with traditional chinese medicine［M］.Beijing:The People's Health Publishing House,2014:20-33.
［8]皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统-通用不良反应术语标准4.0版［J］.肿瘤,2012,32(2):142-144. GAO WJ,LIU YY,YUAN CR.International evaluation system for adverse events of chemotherapeutic drugs in cancer treatment:CTCAE v4.0［J］.Tumor,2012,32(2):142-144.
［9]鲍建敏.非小细胞肺癌患者中医辨证分型与临床分期淋巴结转移的相关性研究［J］.中国中医药科技,2018,25(4):459-460,473. BAO JM.Study on correlation between differentiation of chinese medicine syndromes and clinical stages,lymphatic metastasis of patients with non-small-cell lung cancer［J］.Chinese Chinese Medicine Science and Technology,2018,25(4):459-460,473.
［10]肖琳,王志武,宣立功,等.晚期非小细胞肺癌安罗替尼治疗后中医证型与近期疗效相关性因素的分析［J］.辽宁中医杂志,2022,49(9):74-78. XIAO L,WANG ZW,XUAN LG,et al.Analysis of TCM syndromes and related factors after anlotinib treatment in advanced non-small cell lung cancer［J］.Liaoning Journal of Traditional Chinese Medicine,2022,49(9):74-78.
［11]GE MH,HUANG P,LU XY,et al.Expert consensus on off-label use of anlotinib［J］.Modern Applied Pharmacy in China,2021,38(24):3102-3107.
［12]HAN B,LI K,WANG Q,et al.Third-line treatment:A randomized,double-blind,placebo-controlled phase III ALTER-0303 study-Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC［J］.J Clin Oncol,2017,35(15 suppl):9053.
［13]崔广华,杨宇.安罗替尼在晚期恶性肿瘤治疗中的研究进展［J］.现代肿瘤医学，2022，30（16）：3032-3036. CUI GH,YANG Y.Research progress of anlotinib in the treatment of advanced malignant tumors［J］.Modern Oncology,2022,30（16）：3032-3036.
［14]张帅,王艳.安罗替尼治疗恶性肿瘤的临床进展［J］.现代肿瘤医学，2023，31（19）：3697-3701. ZHANG S,WANG Y.Clinical progress of anrotinib in the treatment of malignant tumor［J］.Modern Oncology，2023，31（19）：3697-3701.
［15]HAN B,LI K,ZHAO Y,et al.Anltonib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomized phase Ⅱ trial(ALTER0302)［J］.Br J Cancer,2018,118(5):654-661.
［16]SUN Y,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors［J］.J Hematol Oncol,2016,9(1):105.
［17]WANG J,ZHAO Y,WANG Q,et al.Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment［J］.Cancer Biol Med,2018,15(4):443-451.
［18]卢美君,赵燕仪,康马飞.影响安罗替尼临床疗效和预后的多因素分析［J］.现代肿瘤医学,2022,30(10):1831-1835. LU MJ,ZHAO YY,KANG MF.Analysis of multiple factors affecting clinical efficacy and prognosis of anlotinib［J］.Modern Oncology,2022,30(10):1831-1835.
［19]季栋梁.安罗替尼和厄洛替尼治疗晚期非鳞非小细胞肺癌的临床疗效与安全性分析［J］.中国现代应用药学,2021,38(22):2886-2889. JI DL.Analysis of the clinical efficacy and safety of anlotinib and erlotinib in the treatment of advanced non-squamous non-small cell lung cancer［J］.Modern Applied Pharmacy in China,2021,38(22):2886-2889.
［20]潘晓葶,戴安伟.安罗替尼联合PD-1单抗三线及以上治疗晚期非小细胞肺癌的疗效和安全性［J］.现代肿瘤医学,2023,31(16):3024-3027. PAN XT,DAI AW.Efficacy and safety of allotinib combined with PD-1 monoclonal antibody in the treatment of advanced non-small cell lung cancer［J］.Modern Oncology,2023,31(16):3024-3027.
［21]王然,俞远东.晚期胆管癌安罗替尼维持治疗的疗效及安全性分析［J］.现代肿瘤医学,2023,31(17):3232-3236. WANG R,YU YD.Efficacy and safety analysis of antirotinib maintenance therapy for advanced cholangiocarcinoma［J］.Modern Oncology,2023,31(17):3232-3236.
［22]徐晨,王胜,李春颖.安罗替尼治疗晚期非小细胞肺癌的系统评价［J］.河北医学,2021,27(8):1265-1271. XU C,WANG S,LI CY.Systematic evaluation of anlotinib in treatment of advanced non-small cell lung cancer［J］.Hebei Medicine,2021,27(8):1265-1271.
［23]任静.安罗替尼对脂质代谢的调节作用及机制研究［D］.天津:天津医科大学,2019. REN J.Study on the regulatory effect and mechanism of anrotinib on lipid metabolism［D］.Tianjin:Medical University of Tianjin,2019.
［24]SI X,LI Z,WANG H,et al.Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer:Experiences in ALTER-0303:Adverse event management of anlotinib［J］.Thorac Cancer,2019,10(3):551-556.
［25]杨雳,何杰,任召强,等.安罗替尼治疗晚期非小细胞肺癌效果和安全性的Meta分析［J］.中国医药,2020,15(4):545-549. YANG L,HE J,REN ZQ,et al.Efficacy and safety of anlotinib in treatment of advanced non-small cell lung cancer:a Meta analysis［J］.Chinese Medicine,2020,15(4):545-549.
［26]蒋中秀，崔国元，张晓晔.安罗替尼治疗晚期非小细胞肺癌的疗效与安全性的Meta分析［J］.现代肿瘤医学，2021,29(02):242－248. JIANG ZX,CUI GY,ZHANG XY.Efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer:A Meta-analysis［J］.Modern Oncology，2021,29(02):242－248.
［27]曹雨晴,张瑞,师莹莹,等.文献报道安罗替尼不良反应分析［J］.医药导报,2022,41(7):1052-1055. CAO YQ,ZHANG R,SHI YY,et al.Analysis of adverse drug reactions of anlotinib reported in literature［J］.Medical Guide,2022,41(7):1052-1055.
［28]宋佳伟,王媛媛,陈慧娟,等.安罗替尼药物利用评价标准的建立及应用［J］.中国新药与临床杂志,2022,41(4):245-249. SONG JW,WANG YY,CHEN HJ,et al.Establishment and application of drug use evaluation criteria for anlotinib［J］.The Chinese Journal of New Drugs and Clinical Medicine,2022,41(4):245-249.
［29]罗详冲.安罗替尼治疗肺癌的临床研究进展［J］.中国肿瘤生物治疗杂志,2019,26(6):710-714. LUO XC.Clinical research progress of anlotinib in the treatment of lung cancer［J］.Chinese Journal of Biotherapy for Oncology,2019,26(6):710-714.

Memo

Memo:
江苏省药学会天晴医院药学科研项目(编号：Q202026)；江苏省苏州市民生科技-医疗卫生应用基础研究项目(编号：SYSD2020193)
Last Update: 2024-03-29